Not real patients.
LYNPARZA is not approved for
patients under 18 years of age.
These are the results of a study that evaluated adults with HER2-negative, high-risk early breast cancer with an inherited BRCA mutation. Women and men in the study had surgery and received chemotherapy either before or after their surgery. Patients with hormone receptor–positive breast cancer may have also received hormonal therapy.
In this study, 921 adults were treated with LYNPARZA and 915 were treated with placebo.
PATIENTS WERE TREATED FOR UP TO 1 YEAR,
unless they experienced significant side effects or their cancer returned.
Your healthcare provider will decide how long you stay on treatment with LYNPARZA.
42%
Lower risk of cancer returning
LYNPARZA reduced the risk of cancer returning by 42% in early breast cancer compared with placebo.
This means that there was a lower chance of breast cancer returning, new cancers growing, or death compared with placebo.
815 out of 921 patients treated with LYNPARZA did not have their breast cancer return, new cancers grow, and were alive compared with 737 out of 915 patients treated with placebo.
32%
Lower risk of death
LYNPARZA lowered the risk of death by 32% in early breast cancer compared with placebo.
In this study, 846 out of 921 patients treated with LYNPARZA were alive at the time of follow-up as compared with 806 out of 915 treated with placebo.
These data are a secondary conclusion, or result, of the overall study.
LYNPARZA may cause serious side effects, including:
Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.
LYNPARZA is a prescription medicine used to treat adults who have:
It is not known if LYNPARZA is safe and effective in children.
LYNPARZA may cause serious side effects, including:
Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.
Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.
Your healthcare provider will do blood tests to check your blood cell counts:
Lung problems (pneumonitis). Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis. Pneumonitis may lead to death.
Blood clots (venous thromboembolism). Some people may develop a blood clot in a deep vein, usually in the leg (venous thrombosis) or a clot in the lungs (pulmonary embolism), which may be severe or lead to death. Tell your healthcare provider right away if you have any symptoms such as pain or swelling in an extremity, shortness of breath, chest pain, breathing that is more rapid than normal (tachypnea), or heart beats faster than normal (tachycardia). Your healthcare provider will monitor you for these symptoms and may prescribe blood thinner medicine.
Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LYNPARZA and certain other medicines may affect how LYNPARZA works and may cause side effects.
How should I take LYNPARZA?
What should I avoid while taking LYNPARZA?
Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.
LYNPARZA may cause serious side effects (see above). The most common side effects of LYNPARZA when used alone are:
The most common side effects of LYNPARZA when used in combination with bevacizumab are:
The most common side effects of LYNPARZA when used in combination with abiraterone are:
These are not all the possible side effects of LYNPARZA. Call your healthcare provider for medical advice about side effects. You may report side effects related to AstraZeneca products(Opens in new window).
Please see complete Prescribing InformationLink opens PDF in a new tab, including Medication GuideLink opens PDF in a new tab.